Low-Dose Naltrexone to Improve Physical Health in Patients

Recruiting

18-90 years

All

Phase 2

10 participants needed

1 Location

Brief description of study

The purpose of this study is to see whether a drug called naltrexone improves health-related quality of life in patients with vasculitis. Naltrexone is a prescription drug approved for a different reason at a higher dose than the dose used in this study. However, “low dose naltrexone” is widely used, without insurance coverage, for a wide range of conditions associated with pain or fatigue. We hope to learn more about the impact of low dose naltrexone on the symptoms caused by vasculitis.

Detailed description of study

Patients must have a diagnosis of vasculitis and significantly low quality of life caused by some combination of pain, fatigue, poor physical health, and difficulty carrying out activities. Medication used to treat vasculitis, pain, and fatigue must be stable for 12 weeks before a patient can enroll in the study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Polyarteritis nodosa, Vasculitis, Microscopic Polyangiitis, MPA, Giant Cell Arteritis, GCA, Takayasu's Arteritis, TAK, Granulomatosis with Polyangiitis, GPA, Eosinophilic Granulomatosis with polyangiitis
Age: Between 18 Years - 90 Years
Gender: All

1. Patients must first have a diagnosis of the following types of vasculitis:

Giant cell arteritis (GCA)
Takayasu’s arteritis
Polyarteritis nodosa (PAN)
Granulomatosis with polyangiitis (GPA // Wegener’s)
Microscopic polyangiitis (MPA)
Eosinophilic granulomatosis with polyangiitis (EGPA // Churg-Strauss)

2. Patients must also have a significantly low quality of life caused by some combination of pain, fatigue, poor physical health, and difficulty carrying out activities.

3. Medication used to treat vasculitis, pain, and fatigue must be stable for 12 weeks before a patient can enroll in the study.

4. Disease activity must also be in remission or have very low activity

Updated on 01 Aug 2024. Study ID: 829492

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).